Hiroshi Koga

Hiroshi Koga

Auto-generated profile, based on publicly available information

Hiroshi Koga

Department of Dermatology Kurume University School of Medicine Kurume, Fukuoka Japan

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
HIHiroaki Iwata
Hiroaki Iwata
AVArtem Vorobyev
Artem Vorobyev
HKHiroshi Koga
Hiroshi Koga
ARAndreas Recke
Andreas Recke
DZDetlef Zillikens
Detlef Zillikens
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig
Epidermolysis bullosa acquisita (EBA) is an orphan autoimmune disease. Several clinical phenotypes have been described, but subepidermal blistering is characteristic of all variants. Limited data on clinical and immunopathological characteristics and treatment outcomes in EBA are available. To fill this gap, we collected this information from EBA cases, meeting current diagnostic criteria, published between 1971 and 2016. We identified 1159 EBA cases. This number must be, however, interpreted with caution, as it is not possible to check for multiple reporting. The analysis of all cases indicated that EBA affects all age groups (median: 50 years, range: 1 to 94 years) at an equal gender distribution. Non-mechanobullous (non-MB) forms of EBA were observed in 55% of patients, whereas the mechanobullous variant (MB-EBA) or a combination of both variants was described in 38 or 7% of patients, respectively. Type VII collagen (COL7)-specific autoantibodies were primarily of the IgG isotype, but anti-COL7 IgA, IgM and IgE were also documented. Comparison of the 2 clinical EBA types showed a higher frequency of IgA deposits in non-MB EBA as opposed to MB EBA. Mucous membrane involvement was observed in 23% of patients, and 4.4% of cases were associated with other chronic inflammatory diseases. Of note, IgA deposits were more frequently observed in cases with mucous membrane involvement. Our analysis indicated that EBA is difficult to treat and that the choice of treatment varies widely. Chi square was applied to identify medications associated with complete remission (CR). Considering all EBA cases, intravenous immunoglobulin (IVIG, p = 0.0047) and rituximab (p = 0.0114) were associated with CR. Subgroup analysis demonstrated that no treatment was associated with CR for non-MB EBA, while IVIG (p = 0.003) was associated with CR in MB EBA. Within the limitations of the study, we here document the clinical and immunopathological characteristics and treatment outcomes in a large cohort of EBA patients. The observed associations of single drugs with treatment outcome may serve as a guide to develop clinical trials.

15 May 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
WPWiebke Prüßmann
Wiebke Prüßmann
JPJasper Prüßmann
Jasper Prüßmann
HKHiroshi Koga
Hiroshi Koga
ARAndreas Recke
Andreas Recke
HIHiroaki Iwata
Hiroaki Iwata
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig
Mucocutaneous blistering is characteristic of autoimmune bullous dermatoses (AIBD). Blisters are caused by autoantibodies directed against structural components of the skin. Hence, detection of specific autoantibodies has become a hallmark for AIBD diagnosis. Studies on prevalence of AIBD autoantibodies in healthy individuals yielded contradictory results. To clarify this, samples from 7063 blood donors were tested for presence of anti-BP180-NC16A, anti-BP230 and anti-Dsg1/3 IgG by indirect immunofluorescence (IF) microscopy using a biochip. Cumulative prevalence of these autoantibodies was 0.9 % (CI: 0.7–1.1 %), with anti-BP180-NC16A IgG being most prevalent. Validation of IF findings using ELISA confirmed presence of autoantibodies in 7/15 (anti-Dsg1), 6/7 (anti-Dsg3), 35/37 (anti-BP180-NC16A) and 2/3 (anti-BP230) cases. Moreover, in 16 samples, anti-BP180-NC16A autoantibody concentrations exceeded the cut-off for the diagnosis of bullous pemphigoid. Interestingly, these anti-BP180-NC16A autoantibodies from healthy individuals formed immune complexes with recombinant antigen and dose-dependently activated neutrophils in vitro. However, fine-epitope mapping within NC16A showed a different binding pattern of anti-BP180-NC16A autoantibodies from healthy individuals compared to bullous pemphigoid patients, while IgG subclasses were identical. Collectively, we here report a low prevalence of AIBD autoantibodies in a large cohort of healthy individuals. Furthermore, functional analysis shows differences between autoantibodies from healthy donors and AIBD patients.

10 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVArtem Vorobyev
Artem Vorobyev
YGYask Gupta
Yask Gupta
TSTanya Sezin
Tanya Sezin
HKHiroshi Koga
Hiroshi Koga
YBYannic C. Bartsch
Yannic C. Bartsch
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig
Phenotypic variation of quantitative traits is orchestrated by a complex interplay between the environment (e.g. diet) and genetics. However, the impact of gene-environment interactions on phenotypic traits mostly remains elusive. To address this, we feed 1154 mice of an autoimmunity-prone intercross line (AIL) three different diets. We find that diet substantially contributes to the variability of complex traits and unmasks additional genetic susceptibility quantitative trait loci (QTL). By performing whole-genome sequencing of the AIL founder strains, we resolve these QTLs to few or single candidate genes. To address whether diet can also modulate genetic predisposition towards a given trait, we set NZM2410/J mice on similar dietary regimens as AIL mice. Our data suggest that diet modifies genetic susceptibility to lupus and shifts intestinal bacterial and fungal community composition, which precedes clinical disease manifestation. Collectively, our study underlines the importance of including environmental factors in genetic association studies.

1 November 2016 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
HKHiroshi Koga
Hiroshi Koga
ARAndreas Recke
Andreas Recke
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
HPHendri H. Pas
Hendri H. Pas
MJMarcel F. Jonkman
Marcel F. Jonkman
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig

2 April 2021 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
XLXiaoguang Li
Xiaoguang Li
HQH. Qian
H. Qian
YNY. Natsuaki
Y. Natsuaki
HKH. Koga
H. Koga
TKT. Kawakami
T. Kawakami
Takashi HashimotoTakashi Hashimoto
Takashi Hashimoto

24 February 2015 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AIAkiko Imanishi
Akiko Imanishi
CTChiharu Tateishi
Chiharu Tateishi
HIHisayoshi Imanishi
Hisayoshi Imanishi
JSJunko Sowa‐Osako
Junko Sowa‐Osako
HKHiroshi Koga
Hiroshi Koga
THTakashi Hashimoto
Takashi Hashimoto